2,4-Imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
| Title | Journal |
|---|---|
| TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. | Toxicology and applied pharmacology 20160915 |
| In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. | Molecular endocrinology (Baltimore, Md.) 20121101 |
| Discovery of diarylhydantoins as new selective androgen receptor modulators. | Journal of medicinal chemistry 20121011 |
| Steroid derivatives as pure antagonists of the androgen receptor. | The Journal of steroid biochemistry and molecular biology 20121001 |
| Nilutamide. | Acta crystallographica. Section E, Structure reports online 20120301 |
| Anti-androgen effects of cypermethrin on the amino- and carboxyl-terminal interaction of the androgen receptor. | Toxicology 20120226 |
| Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. | Journal of clinical immunology 20120201 |
| N-[3-(4-Fluoro-benz-yl)-2,4-dioxo-1,3-diaza-spiro-[4.5]dec-8-yl]-2-methyl-benzene-sulfonamide. | Acta crystallographica. Section E, Structure reports online 20120101 |
| N-{3-[2-(4-Fluoro-phen-oxy)eth-yl]-2,4-dioxo-1,3-diaza-spiro-[4.5]decan-7-yl}-4-meth-oxy-benzene-sulfonamide. | Acta crystallographica. Section E, Structure reports online 20120101 |
| Redefining hormone sensitive disease in advanced prostate cancer. | Advances in urology 20120101 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. | Journal of medicinal chemistry 20110922 |
| Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. | Environmental health perspectives 20110801 |
| Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. | Korean journal of urology 20110701 |
| N-{3-[2-(4-Fluoro-phen-oxy)eth-yl]-2,4-dioxo-1,3-diaza-spiro-[4.5]decan-7-yl}-4-methyl-benzamide. | Acta crystallographica. Section E, Structure reports online 20110601 |
| Two panels of steroid receptor luciferase reporter cell lines for compound profiling. | Combinatorial chemistry & high throughput screening 20110501 |
| Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. | The Prostate 20110401 |
| Castration-resistant prostate cancer: targeted therapies and individualized treatment. | The oncologist 20110301 |
| Current treatment strategies for castration-resistant prostate cancer. | Korean journal of urology 20110301 |
| Androgen receptor-mediated regulation of the anti-atherogenic enzyme CYP27A1 involves the JNK/c-jun pathway. | Archives of biochemistry and biophysics 20110215 |
| Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. | Journal of medicinal chemistry 20110113 |
| Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. | Urologic oncology 20110101 |
| Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. | OncoTargets and therapy 20110101 |
| Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. | Cancer management and research 20110101 |
| Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. | Journal of medical case reports 20110101 |
| Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. | Frontiers in pharmacology 20110101 |
| New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. | Prostate cancer 20110101 |
| Effect of Turkish propolis extracts on proteome of prostate cancer cell line. | Proteome science 20110101 |
| Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. | Drug, healthcare and patient safety 20110101 |
| Molecular targets for radiation oncology in prostate cancer. | Frontiers in oncology 20110101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice. | The Journal of antimicrobial chemotherapy 20100901 |
| Words of wisdom. Re: Does oral antiandrogen use before leuteinizing hormone-releasing therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Oh WK, Landrum MB, Lamont EB, et al. Urology 2010;75:642-7. | European urology 20100801 |
| Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. | FEBS letters 20100603 |
| Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. | Endocrinology 20100401 |
| Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor. | Journal of biomedical science 20100101 |
| A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. | Journal of translational medicine 20100101 |
| The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. | Biology direct 20100101 |
| Maximal androgen blockade for advanced prostate cancer. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| Hormonal therapy of prostate cancer. | Progress in brain research 20100101 |
| Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises. | International journal of pediatric endocrinology 20100101 |
| Down-regulation of phosphoglucomutase 3 mediates sulforaphane-induced cell death in LNCaP prostate cancer cells. | Proteome science 20100101 |
| Fasting and cancer treatment in humans: A case series report. | Aging 20091201 |
| Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. | International journal of radiation oncology, biology, physics 20091115 |
| Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. | International journal of radiation oncology, biology, physics 20091001 |
| Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. | PLoS computational biology 20090601 |
| Fulminant hepatic failure due to nilutamide hepatotoxicity. | Digestive diseases and sciences 20090401 |
| CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. | British journal of cancer 20090310 |
| Impact level of dihydrotestosterone on the hypothalamic-pituitary-leydig cell axis in men. | International journal of andrology 20090201 |
| Genotoxic and endocrine activities of bis(hydroxyphenyl)methane (bisphenol F) and its derivatives in the HepG2 cell line. | Toxicology 20090108 |
| Role of maximum androgen blockade in advanced prostate cancer. | Indian journal of urology : IJU : journal of the Urological Society of India 20090101 |
| Watchful waiting beats androgen deprivation therapy in early prostate cancer. | Journal of the National Cancer Institute 20081105 |
| Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. | The Journal of urology 20081001 |
| Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080715 |
| Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). | Cancer 20080601 |
| Delayed dark adaptation caused by nilutamide. | Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20080601 |
| Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism. | Chemical research in toxicology 20080401 |
| Maximal androgen blockade for advanced prostate cancer. | Best practice & research. Clinical endocrinology & metabolism 20080401 |
| Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide. | Journal of medicinal chemistry 20080327 |
| The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. | BMC cell biology 20080101 |
| FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. | BMC bioinformatics 20080101 |
| Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. | PloS one 20080101 |
| A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. | Journal of hematology & oncology 20080101 |
| Strategies for prostate cancer prevention: Review of the literature. | Indian journal of urology : IJU : journal of the Urological Society of India 20080101 |
| Role of vaccine therapy in cancer: biology and practice. | Current oncology (Toronto, Ont.) 20071201 |
| Combined androgen blockade in advanced prostate cancer: looking back to move forward. | Clinical genitourinary cancer 20070901 |
| A bifunctional colchicinoid that binds to the androgen receptor. | Molecular cancer therapeutics 20070801 |
| A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. | Molecular cancer therapeutics 20070701 |
| Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. | The Prostate 20070601 |
| Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. | Asian journal of andrology 20070301 |
| Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor. | Biochemical and biophysical research communications 20070216 |
| Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay. | Chemosphere 20070101 |
| In silico prediction of pregnane X receptor activators by machine learning approaches. | Molecular pharmacology 20070101 |
| New therapeutic targets in the treatment of prostate cancer. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones. | Molecular pharmacology 20061201 |
| Role of 5 alpha-reductase inhibitors in the management of prostate cancer. | Clinical interventions in aging 20061201 |
| Bioactivation and hepatotoxicity of nitroaromatic drugs. | Current drug metabolism 20061001 |
| [Keyrole of endocrinology in the victory against prostate cancer]. | Bulletin du cancer 20060901 |
| Antiandrogen treatments in locally advanced prostate cancer: are they all the same? | Journal of cancer research and clinical oncology 20060801 |
| GREB1 is a novel androgen-regulated gene required for prostate cancer growth. | The Prostate 20060601 |
| Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. | Current oncology (Toronto, Ont.) 20060601 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Combined androgen blockade: an update. | The Urologic clinics of North America 20060501 |
| Recent progress in hormonal therapy for advanced prostate cancer. | Current opinion in urology 20060501 |
| Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. | Pharmaceutical research 20060401 |
| Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells. | Fertility and sterility 20060401 |
| Metabolism of nilutamide in rat lung. | Biochemical pharmacology 20060112 |
| Androgen receptor activities of p,p'-DDE, fenvalerate and phoxim detected by androgen receptor reporter gene assay. | Toxicology letters 20060105 |
| The role of steroids in follicular growth. | Reproductive biology and endocrinology : RB&E 20060101 |
| Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. | Bioorganic & medicinal chemistry 20051115 |
| Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. | Free radical biology & medicine 20051001 |
| Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. | BJU international 20051001 |
| A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. | BJU international 20051001 |
| Nontranscriptional regulation of cardiac repolarization currents by testosterone. | Circulation 20050920 |
| Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. | BJU international 20050901 |
| Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. | The Journal of urology 20050801 |
| [From the finger to the eye!...]. | La Revue de medecine interne 20050701 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. | Urology 20050401 |
| Combined androgen blockade: the case for bicalutamide. | Clinical prostate cancer 20050301 |
| Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. | Journal of medicinal chemistry 20050224 |
| How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? | The Canadian journal of urology 20050201 |
| Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy. | American journal of therapeutics 20050101 |
| Major impact of hormonal therapy in localized prostate cancer--death can already be an exception. | The Journal of steroid biochemistry and molecular biology 20041201 |
| Distribution of nitroreductive activity toward nilutamide in rat. | Toxicology and applied pharmacology 20041115 |
| Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera. | Journal of medicinal chemistry 20041104 |
| Monotherapy in advanced prostate cancer: an overview. | Experimental oncology 20040901 |
| Interstitial lung disease associated with drug therapy. | British journal of cancer 20040801 |
| Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20040601 |
| Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. | Urologia internationalis 20040101 |
| Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans. | American journal of therapeutics 20040101 |
| Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. | Chemical research in toxicology 20031201 |
| [Fatal fulminating hepatitis induced by nilutamide]. | Gastroenterologie clinique et biologique 20031201 |
| Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate. | Journal of medicinal chemistry 20031120 |
| Steroids control the aromatase gene expression in purified germ cells from the adult male rat. | Journal of molecular endocrinology 20030801 |
| Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. | The Journal of urology 20030501 |
| The role of antiandrogen monotherapy in the treatment of prostate cancer. | BJU international 20030301 |
| Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. | Molecular pharmacology 20030101 |
| Therapeutic androgen receptor ligands. | Nuclear receptor signaling 20030101 |
| The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. | British journal of cancer 20021118 |
| Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. | Annals of internal medicine 20021001 |
| Antiandrogen monotherapy: indications and results. | Urology 20020901 |
| Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. | European urology 20020801 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| [The role of bicalutamide in the treatment of prostate cancer]. | Harefuah 20020401 |
| Flavonoids can block PSA production by breast and prostate cancer cell lines. | Clinica chimica acta; international journal of clinical chemistry 20020301 |
| [Respiratory side-effects of drugs]. | Nederlands tijdschrift voor geneeskunde 20020126 |
| Nilutamide: possible utility as a second-line hormonal agent. | Urology 20011201 |
| Nilutamide-induced neutropenia. | BJU international 20011101 |
| Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. | Urology 20010801 |
| Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. | The Prostate 20010615 |
| Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. | Journal of medicinal chemistry 20010524 |
| Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. | Urology 20010401 |
| Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. | BJU international 20010101 |
| Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer. | Molecular urology 20010101 |
| Androgen deprivation and other treatments for advanced prostate cancer. | Reviews in urology 20010101 |
| Flare Associated with LHRH-Agonist Therapy. | Reviews in urology 20010101 |
| Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. | Endocrinology 20000201 |
| Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. | Urology 19970401 |
| Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer? | Progress in clinical and biological research 19900101 |